ADVENT On Air

Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD

2024-08-08

Join Drs. April Armstrong and Lisa Beck for a conversation around the long-term burden and effects of AD. They will discuss the underlying pathophysiology of AD and how early intervention and disease modification may impact disease course.ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.This podcast is intended for healthcare professionals only.Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) creditsSpeaker disclosures: April Armstrong, MD, MPH has served as a research investigator, scientific advisor, or speaker to AbbVie, Amgen, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Mindera, Nimbus, Novartis, Ortho, Sun, Dermavant, Dermira, Sanofi, Takeda, Organon, Regeneron, Pfizer and Ventyx Lisa Beck MD, consults for Abbvie, Allakos, Arcutis Biotherapeutics, Arena Pharmaceuticals, Aslan Pharma, Astria Therapeutics, Celldex, Dermavent, DermTech, Escient Pharma, Eli Lilly Company, Evelo Biosciences, Galderma, Incyte, Janssen, LEO Pharma, Merck, Nektar Therapeutics, Numab Therapeutics, Pfizer, Proteologix, Rapt Therapeutics, Regeneron, Ribon Therapeutics, Sanofi/Genzyme, Sanofi-Aventis, Sitryx Therapeutics, Stealth BioTherapeutics, Trevi Therapeutics, Union Therapeutics, Xencor and Yuhan and has been an Investigator for Abbvie, Astra-Zeneca, DermTech, Kiniksa, Pfizer, Regeneron, Ribon Therapeutics and Sanofi. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.MAT-GLB-2401395 - 2.0 - 08/2026MAT-US-2407636 v2.0 - P 08/2026 Updated Expiration Date: 08/04/2028

Número de episodios

28

Último episodio

2026-10-08

¿Donde puedes escuchar?

The latest updates in type 2 inflammatory science, brought to you by leading experts in the field.
The ADVENT On Air podcast will feature scientific conversations that explore new research into the pathologies and modalities for a range of diseases linked to type 2 inflammation (atopic dermatitis, asthma, prurigo nodularis, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis). This podcast is instrumental for healthcare professionals focused on allergy, dermatology, gastroenterology, and diseases of the upper and lower airways who want to stay at the forefront of this complex, evolving disease area.
Subscribe to the ADVENT On Air podcast channel to receive notifications when new episodes are released. To explore additional educational materials for HCPs about dermatology, pulmonology, rhinology, and gastroenterology, visit ADVENTprogram.com.
This podcast is produced as part of ADVENT, a medical education non-promotional program organized by Sanofi and Regeneron, and is intended for healthcare professionals.

©2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.
MAT-GLB-2302644 v2.0 07/2023
MAT-US-2304947 v1.0-P Exp. Date 07/07/2025